Introduction {#s1}
============

Evans Syndrome (ES) is a rare condition, first described by Evans in 1951 ([@B1]) as the association of Autoimmune Hemolytic Anemia (AIHA) and Immune Thrombocytopenia (ITP) and it was considered an idiopathic autoimmune disease. Until now different definitions for ES have been used in literature. Some authors defined ES as the presence of an autoimmune destruction of at least 2 cell lineages, while others requested the presence of AIHA and ITP regardless of autoimmune neutropenia (AIN). Others restricted diagnosis of ES only to patients with no identifiable underlying cause of AIHA with ITP ([@B2], [@B3]). Finally, there were authors considering secondary forms too ([@B4], [@B5]), most commonly primary immunodeficiencies (PID) and rheumatological disease. Fischer et al. reported a risk of autoimmune cytopenia 120 times higher in patients with PID than general population ([@B6]). Most frequently, in patients affected by PID, causes of ES were Common Variable Immunodeficiency (CVID) and Autoimmune Lymphoproliferative Syndrome (ALPS) ([@B7], [@B8]) whereas in rheumatological disease, Systemic Lupus Erythematosus (SLE) and Antiphospholipid Antibody Syndrome (APS) ([@B9]). For that reason, some authors considered useful screening for ALPS, CVID, SLE, and APS in children with chronic single lineage autoimmune cytopenia or multi-lineage autoimmune cytopenias and search for HIV infection in adolescents ([@B4], [@B10]). Hematological manifestations often precede the whole clinical onset of the immunodeficiency and it is only with further investigation that primary immunodeficiency is revealed. We hypothesized that recognition of an immunological background and of the cause of secondary ES could be useful to assess prognosis correctly and necessary for a proper therapeutic choice, especially regarding immunomodulators and corticosteroid-sparing agents ([@B4], [@B8], [@B11]). Although literature suggests an association of ES with primary immune dysregulation, data mainly come from small cohorts of adult patients. Considering that characteristics and outcomes of children with ES are not well-documented, this study aims to describe natural history of autoimmune multi-lineage cytopenias in children referred to our center.

Materials and Methods {#s2}
=====================

Between 2002 and 2018, 12 patients with Evans syndrome referred to the Pediatric Onco-Hematology Unit of Bologna and data regarding clinical history and immuno-autoimmune laboratory tests were retrospectively collected. Internal review board (IRB) approval was obtained at S. Orsola-Malpighi Hospital for the study. Written informed consent was previously obtained from children\'s parents. Population included pediatric patients (age 0--18 at onset of cytopenia) with at least two concurrent or sequential autoimmune cytopenias (ITP, AIHA, AIN). Secondary forms were included and idiopathic ES was considered as an exclusion diagnosis. According to international working group criteria, ITP diagnosis was based on a platelet count of \<100 10^9^/L ([@B12]). AIHA was defined as anemia (Hb \< −2SDS) and a positive direct antiglobulin test associated to signs of hemolysis (hemoglobin reductions, reticulocytosis, unconjugated hyperbilirubinemia, elevated lactate dehydrogenase, and low haptoglobin) ([@B13]). AIN was defined as an absolute neutrophil count \<1.0 10^9^/L for 6 months after exclusion of other causes (e.g., drugs, infections, or known genetic mutation) ([@B14]). In secondary ES cases, diagnosis of immuno-rheumatological disorders was made according to recent literature. CVID was defined according to revised ESID diagnostic criteria[^1^](#fn0001){ref-type="fn"}, ALPS according to 2009 NIH International workshop ([@B15]), Mixed Connective Tissue Disease (MCTD) according to recent literature ([@B16]), and SLE according to the SLE International Collaborating Clinics classification ([@B17], [@B18]). For each patient demographic data, clinical presentation, underlying diagnosis, treatments, and outcome were reported ([Table 1](#T1){ref-type="table"}). Lymphocyte subset, immunoglobulin dosages, screening for autoantibodies, and vaccine responses (Tetanus toxoid) were always collected. When ALPS was suspected, TCRα/β+CD4--CD8-- Double Negative T cell (DNT) counts and vitamin B12 levels were investigated. *In vitro* assessment of Fas-mediated apoptosis was performed in patients with DNT \> 2.5%, since it is considered a sensitive first--line screening test ([@B19]--[@B21]) ([Table 2](#T2){ref-type="table"}). Germline or somatic FAS mutations were tested in patients with selected ALPS clinical and laboratory features. One patient was lost after 1 year of follow up before the genetic analysis were performed. TACI mutations were investigated in children affected by CVID. Regarding severe hypogammaglobulinemia and B cell deficiency (with a complete lack of CD27+IgD-- switched memory B cells and an expansion of the B cell subset CD21loCD38lo and CD27+IgD+ unswitched memory) of the patient with Rubinstein Taybi Syndrome, genetic analysis for mutations in BAFF-R and TACI genes were undertaken. All these gene analyses were performed by Sanger sequencing. All data were collected before the administration of immunomodulant therapies or after suspension for at least 3 months. For patients with secondary forms, data were acquired at the time of diagnosis.

###### 

Patients characteristics.

       **Sex/Age at onset**   **Presenting cytopenia**   **Subsequent cytopenia**   ***N* of acute episodes (average period)**   **Status at FUP**   **FUP (years)**   **Hepato spleno megaly**   **Infection**                               **Others organs**                                   **Diagnosis (Genetics)**   **Age at dg**   **IVIG (infusions)**   **Steroids (cycles)**         **Other therapy**
  ---- ---------------------- -------------------------- -------------------------- -------------------------------------------- ------------------- ----------------- -------------------------- ------------------------------------------- --------------------------------------------------- -------------------------- --------------- ---------------------- ----------------------------- -----------------------------------
  1    F/12                   ITP                        AIHA                       1                                            ITP                 4                 No                                                                     Previous inflam. diarrhea                                                                      1                      Several (in other hospital)   
  2    M/15                   ITP + AIN                  AIHA                       2 (4 months)                                 --                  1                 No                                                                                                                                                                    2                                                    
  3    F/9                    AIHA                       ITP                        2 (2 years)                                  Resolved            3                 No                                                                                                                                                                    1                      2                             
  4    F/8                    ITP, AIHA                                             5 (1 years)                                  Resolved            7                 Yes                                                                                                                                                                   12                     2                             MMF
  5    F/14                   ITP                        AIHA                       5 (4 months)                                 Resolved            4                 No                                                                     DVT, PE, MPGN                                       SLE                        16              1                      3                             
  6    F/14                   ITP, AIHA                                             4 (1 years)                                  ITP                 4                 Yes                                                                    Thyroiditis psoriasis                               MCTD                       15              1                      4                             MMF
  7    M/9                    ITP                        AIHA                       Chronic ITP                                  ITP                 4                 Yes                                                                    Thyroiditis celiac disease                          CVID (TACI TNFRSF6: neg)   13              2                                                    
  8    M/2                    ITP                        AIHA                       7 (18 months)                                Resolved            14                Yes                        Bronchitis and otitis (CHL), resistant HP   Allergic asthma                                     CVID (TACI, TNFRSF6:neg)   14              2                      2                             IRT
  9    M/8                    ITP                        AIHA                       4 (6 months)                                 Resolved            13                Yes                                                                                                                        ALPS-FAS (TNFRSF6 mut)     9               2                      3                             MMF, Rituximab, IRT
  10   M/2                    ITP, AIHA                                             2 (8 years)                                  ITP                 9                 Yes                        Tympanostomy tube for acute otitis media                                                        CVID (TACI neg)            10              5                      2                             MMF, sirolimus, eltrombopag
  11   F/5                    AIN                        ITP                        6 (2 years)                                  Resolved            17                No                         Bronchiectasis                              Rubinsten Taybi Sdr.                                Low-B RTS (BAFF-R mut)     22              2                      4                             IRT
  12   F/13                   ITP, AIHA, AIN                                        2 (1 month)                                  ITP                 2                 No                                                                     Vitiligo, atopic dermatitis, thyroiditis myositis   SLE                        14              2                                                    Ciclosporin per atopic dermatitis

*AIHA, Autoimmune hemolytic anemia; AIN, Autoimmune neutropenia; ALPS, Autoimmune Lymphoproliferative Syndrome; APS, Antiphospholipid Antibody Syndrome; CID, Combined Immunodeficiecy; CVID, Common Variable Immunodeficiency; CHL, Conductive Hearing Loss; DNT cell, TCRα/β+CD4--CD8-- Double Negative T cell; DVT, deep vein thrombosis; HP, Helicobacter pylori; IRT, Immunoglobulin Replacement Therapy; ITP, Immune Thrombocytopenia; MCTD, Mixed Connective Tissue Disease; MMF, Mycophenolate mofetil; MPGN, Membranoproliferative Glomerulonephritis; PE, Pulmonary Embolism; SLE, Systemic Lupus Erythematosus*.

###### 

Laboratory investigation.

       **Hb Nadir g/dl**   **ANC Nadir μL**   **IgG mg/dl**   **IgA mg/dl**   **IgM mg/dl**   **WBC μL**     **Lymph μL**   **CD3+ %**   **CD4+ %**   **CD4+ μL**   **CD8+ %**   **CD4+/CD8+**   **NK %**   **CD19+ %**   **CD3+ γ+δ+ %**   **CD3+DNT %**   **Fas activity**   **Auto antibodies**                                                                                                 **Vit B12**   **Vaccine response**
  ---- ------------------- ------------------ --------------- --------------- --------------- -------------- -------------- ------------ ------------ ------------- ------------ --------------- ---------- ------------- ----------------- --------------- ------------------ ------------------------------------------------------------------------------------------------------------------- ------------- ----------------------
  1    6.7                                    1,087           105             130             11,560         2,231          76           49           1,093         23           2.13            2^−^       20.9          1.7               1.6                                                                                                                                                    275           
  2    8.5                 620                1,101           102             104             2,080^**−**^   1,248          84^**+**^    53^+^        661           23           2.30            4          10            3                 2.8                                ANA 1:160                                                                                                           855           
  3    6.2                                    928             106             142             11,520         2,926          79^**+**^    41           1,200         34           1.21            6          14            3                 1.5                                                                                                                                                                  
  4    7.5                                    1,114           114             131             6,340          2,110          77           62^**+**^    1,308         32           1.94            8.5        6.5^**−**^    2                 1.8                                                                                                                                                    268           
  5    6.9                                    1,596           237             171             7,380          2,347          63           36           845           22           1.64 ^+^        13         23.5^**+**^                                                        ANA reflex 1:640, ENA/ANA 14, SS-A60+++, SS-ARo52+++, Ro60 240 U/ml, dsDNA 32 IU/ml, CLIgG 54 U/ml, CLIgM 23 U/ml   306           
  6    8.5                                    1,807^**+**^    138             227             6,840          2,161          31^**−**^    16^**−**^    346^−^        12^−^        1.33            5          63^**+**^                                                          ANA reflex 1:640, ENA/ANA 36, RNP70+++, RNPA++, U1RNP 201 U/ml, Tg 1967 U/ml, TPO 95 U/ml                           214           
  7    7.8                                    585^**−**^      21^**−**^       37^**−**^       5,130          1,272^**−**^   79^**+**^    52^**+**^    661           23           2.26            9          12            2                 4,2             NEG                Tg 1238 UI/ml, tTG 126 U/ml                                                                                         961           No
  8    8.3                                    521^**−**^      21^**−**^       26^**−**^       5,730          2,636          87^**+**^    43           1,133         34           1.26            6          5^**−**^      2.6               3.6             NEG                                                                                                                                    994           No
  9    7.2                                    1,590           341^**+**^      22^**−**^       3,610          1,527          76           35           535           28           1.25            13         11            7                 5.6             POS                                                                                                                                    \>2,000       Yes
  10   6.5                                    440^**−**^      55^**−**^       14^**−**^       7,150          1,160^**−**^   61           31           360^−^        26           1.19            5          33.3^**+**^   6                 1                                  ANAreflex 1:320, ENA/ANA 2.3, Sp100+++, AMA M2 +                                                                                  Yes
  11                       329                184^**−**^      6^**−**^        8^**−**^        5,820          2,178          90^**+**^    49           1,067         36           1.36            9          0.9^**−**^    4                 1.6                                                                                                                                                    396           No
  12   9                   710                1,265           183             133             4,490^**−**^   1,440^**−**^   70           39           562           29^−^        1.34            8          20^+^         2                 1                                  ANA reflex 1:640, ENA/ANA 6, SS-A+,Ro52++, SRP ++, dsDNA 21 IU/ml, CLIgM 557 U/ml                                   588           

*Nadir of Hb (Hemoglobin) and ANC (Absolute Neutrophil Count) in patients with AIHA e AIN, Anti-Sm, Anti-Smith antibodies; AMA, Anti-mitochondrial antibodies; ANA, Antinuclear antibodies; CLIgG, Cardiolipin IgG; CLIgM, Cardiolipin IgM; DGP, Deamidated gliadin peptides; DNT cell, TCRα/β+CD4--CD8-- Double Negative T cell; ENA, Extractable Nuclear Antigen Antibodies; RF, Rheumatoid factor; SRP, Signal recognition particle antibodies; tTG, Transglutaminase; Tg, Thyroglobulin; TPO, Thyroid Peroxidase; ^−^: \<2DS; ^+^: \>2DS*.

Results {#s3}
=======

Data of 12 patients with ES, seven females (58%) and five males (42%), referred to the Pediatric Onco-Hematology Unit of Bologna between 2002 and 2018 were retrospectively collected ([Table 1](#T1){ref-type="table"}). Median age at onset of cytopenias was 9 years (range 2--15 years) and median follow-up time was 4 years (range 1--17 years). At presentation multiple cytopenias were found in five children (42%). A girl was diagnosed with AIHA, ITP, and AIN, three children with AIHA and ITP and two with ITP and AIN. In 7 patients (58%), a second cytopenia developed only afterward. Five of these had primarily developed ITP and subsequently AIHA, the other two children developed ITP following AIHA or AIN. Patients experienced a median of four episodes (range 1--7), median time between acute events was 15 months (range 4 months−8 years). Six patients (50%) presented significant hepatosplenomegaly or lymphadenopathy, three children (25%) developed relevant infections (e.g., bronchiectasis pneumonia, tympanostomy tubes). Eight out of 12 (67%) patients were diagnosed for PID or a rheumatological disorder. Five children were diagnosed with PID (42%): three children with CVID (25%), one with ALPS-FAS (8%), and one child affected by Rubinstein Taybi Syndrome had developed a progressive severe B cell deficiency with hypogammaglobulinemia related to a BAFF-R mutation (low B-RTS, 8%) ([@B22]). Three were diagnosed with a rheumatological disease (two with SLE, one with MCTD). Four children (33%), one affected by CVID, also developed another autoimmune disorder (Thyroiditis, Celiac disease, Psoriasis, Vitiligo, Myositis, Membranoproliferative Glomerulonephritis).

Anti-platelet antibodies were detected in all the children and direct antiglobulin test was positive in 11/12 (82%). Only one child was found with anti-neutrophil antibodies (8%). Antinuclear antibody (ANA) positivity was detected in four patients (33%), three of which developed a rheumatological disease subsequently.

Three patients were lymphopenic (25%) all of these were diagnosed with a secondary ES. One was lost after 1 year of follow-up. None of the patients had low rate of CD4+/CD8+ T cells. In four patients (33%), a high DNT count (≥2.5% CD3+ lymphocytes) was found. One of them was diagnosed with ALPS, two with CVID, and one was lost to follow-up before performing other tests. In other three patients with high DNT count a FAS-mediated apoptosis of mitogen-stimulated T cells and gene analysis for TNFRSF6 mutation by Sanger sequencing were performed. In only one child affected by ALPS, the FAS-induced lymphocyte apoptosis assay resulted defective. In this patient germinal TNFRSF6 mutation G286X (c. 856G\>T) not previously described was found.

TACI mutation was not detected in any patient with CVID. In a patient with low B-RTS, no TACI mutations were identified whereas it was detected the previously described BAFF-R monoallelic variant P21R (c.62C\>G) ([@B23]).

B cell count was low in six patients (50%), four of them affected by a PIDs, and high in two girls (17%) both affected by a rheumatological disease. In six patients (50%), altered immunoglobulin levels were found. One girl affected by MCTD showed high IgG value, meanwhile four cases of PID (three CVID, one low-B RTS) revealed low immunoglobulin levels. One patient affected by ALPS showed high IgA and low IgM. The immune responses to vaccines (Tetanus toxoid) resulted normal in child affected by ALPS and absent in low-B RTS and two CVID patients. A patient with CVID maintained protective levels of antibodies in particular against the Tetanus toxoid (with absent B memory IgD+ and switched).

Cytopenias were treated as shown in [Table 1](#T1){ref-type="table"}. All children received first-line treatments with IVIG or corticosteroids. Three children (23%), all diagnosed with an underlying condition, underwent second-line therapies in order to control resistant ITP. One child affected by CVID was treated with Sirolimus and Eltrombopag with partial control of cytopenias. In a girl with MCTD, partial control of ITP and AHIA was achieved after Mycophenolate Mofetil therapy. Rituximab was effective in a child with ALPS even though he had developed a persistent hypogammaglobulinemia and is now undergoing immunoglobulin replacement therapy (IRT). In three children developing AIN, Granulocyte-colony stimulating factor therapy was not required. Two of these, one affected by LES, showed a trilinear cytopenia. Two episodes of ITP were treated with IGIV, whereas AIHA and AIN where mild and hadn\'t required therapies.

At a median follow-up time of 4 years (range 1--17), all 12 patients were alive. In only 7 (58%) good control of cytopenias was achieved. Other five (42%) revealed a chronic ITP partially responsive to second line therapy, out of these, four were diagnosed with a secondary ES. Three patients with a secondary ES (ALPS, CVID, and a patient with Rubinstein Taybi Syndrome) are undergoing immunoglobulin replacement therapy and maintained good hematological values control. Two children affected by CVID maintained protective levels of antibodies.

Discussion {#s4}
==========

This study describes the clinical and laboratory history of 12 patients with ES treated in our Hospital in the last 17 years. Since 1980 ([@B24]), few studies have described the heterogeneity of presenting symptoms and the different underlying etiologies that came to light after an appropriate immune and rheumatological evaluation of children affected by multilineage cytopenias ([@B2], [@B5], [@B24]--[@B26]). Our data highlight ES as a possible early manifestation of an underlying immune disorder, PID or rheumatological disease, especially when cytopenias are persistent-resistant to therapy, with an early-onset or when are associated with lymphadenopathy ([@B7], [@B8], [@B10], [@B23], [@B26]--[@B29]). Particularly, for these patients, a proper laboratory investigation and a careful follow up is necessary to achieve a proper diagnosis. More than a half of our children with ES revealed an immune dysregulation (42% PID, 16% rheumatological disease). According to literature, no correlation between etiology or outcome and timing or sequencing of cytopenias presentation was found ([@B5], [@B25], [@B26], [@B30]). Serum vitamin B12 level was helpful in the differential diagnosis between IgG low-ALPS and DNT high-CVID ([@B31]) in two patients with hypogammaglobulinemia, lymphoproliferation, and raised DNT cell count. Our data also highlight that making a proper diagnosis is essential to ensure optimal management of therapies. For example 10 years ago, Rituximab was effective in treating cytopenias in a patient affected by ALPS but he developed a permanent hypogammaglobulinemia. In these patients other immunomodulatory therapies as mTOR inhibitors or Mycophenolate Mofetil should be preferred and splenectomy avoided for an increased risk of sepsis ([@B32], [@B33]). In our cohort these corticosteroid-sparing agents, used early in treatment, were efficient in two out of 12 patients, one affected by CVID and one by MCTD.

As described in literature, ES might be considered as a dysregulation of the immune system. Different mechanisms, both cellular and humoral immunity, are involved in the immune-mediated cytopenias. Since the 80s\', authors tried to describe and analyze the dysregulation of the immune system reporting a usual reduction of CD4/CD8 ratio, aberrant Th1/Th2 ratio, immunoglobulin levels alterations, IL-10 and IFN-γ increase and TGF-β suppression ([@B34], [@B35]).

As recently resumed by Fischer et al. ([@B6]), a combination of factor can predispose patients with PID to autoimmunity as a defective negative selection of self-reactive T and B cells with high affinity, defective peripheral editing of the B-cell receptor and self-antigen--induced cell death, defective regulatory T cells or molecules, defective clearance of immune complexes and apoptotic cell bodies, gain of function of B- or T-cell activation/effector molecules, homeostatic expansion of self-reactive T lymphocytes, exacerbated production of type I interferon or IL-1. Auto-reactive immunoglobulins could be produced due to an altered B-cell regulation during maturation and tolerance induction or by an altered T--B cells interaction. Especially IgG and rarely IgA and IgM, bound to red blood cells leading to their destruction by antibody-dependent cellular cytotoxicity and/or by the activation of the complement cascade. Neutrophils are attached by antibodies that mostly binds the IgG Fc receptor type 3b (FccIIIb receptor). Also platelets could be opsonized and be prematurely removed by the reticulo-endothelial system. In ALPS, the defect of T-cell development and FAS apoptotic pathway leads to an abnormal lymphocytes survival with lymphoproliferation and secondarily affects B cells resulting in an antibody-mediated autoimmunity ([@B4], [@B5], [@B30], [@B36], [@B37]).

Despite for IVIG, an immune-modulating mechanism has been proposed ([@B38]--[@B40]) in patients with secondary ES the resistance to therapy could be related to the persistence of long-lived plasma cells secreting pathogenic autoantibodies resistant to immunomodulatory and B cell-depletion therapies ([@B28]). Our three patients with a secondary ES receiving Immunoglobulin Replacement Therapy all maintain good hematological control.

In this scenario, recent coming of Next Generation Sequencing (NGS) dramatically changed the diagnostic workup of ES. The rapid reduction in costs and analysis times of these techniques has made it possible to routinely apply them in the evaluation of the patients with ES. This helped clinicians to better characterize the genetic profile and pathological mechanisms of patients with PID with a non-specific phenotype. In particular NGS target panels represent a powerful approach and could be really efficient when the diagnostic suspicion is relatively circumscribed while Whole Exome Sequencing find an application in conditions where the phenotype overlaps more than one PID. As recently reported in literature, these techniques have allowed finding many novel mutations in patients with PID associated with ES. In particular LRBA (Lipopolysaccharide-Responsive Beige-like an Anchor protein) and CTLA-4 (Cytotoxic T Lymphocyte Antigen-4) defects were described in patients with autoimmune cytopenias, lymphoproliferation, and humoral immune deficiency ([@B41]--[@B44]). LRBA colocalize in endosomal vesicles with CTLA-4 and its deficiency increases CTLA-4 turnover. CTLA4, upregulated in activated conventional T cells and constitutively expressed in FoxP3+ regulatory ones, acts with a competitive mechanism with CD28 for binding B7 molecules ([@B45]). In patients with increased frequency of infections, autoimmune cytopenias and lymphoid hyperplasia these techniques allowed discovery a gain-of-function of PI-3-kinase, activated downstream of CD28 ligation and involved in B-cell proliferation and survival signaling ([@B45], [@B46]), or that of STAT3, involved in the suppression of Treg function and cytokine signaling ([@B45], [@B47]). Furthermore, thanks to Whole Exome Sequencing a homozygous mutation of TPP2, a postproteaosomal cytosolic protease, were found in 6 patients with early-onset Evans syndrome, respiratory infection, and developmental delay ([@B48], [@B49]). For some of these genetic mutations, targeted therapies with a reduced toxicity profile are under investigation for the opportunity of improving outcome ([@B11]).

Due to the rare nature of pediatric ES and refractory cytopenias, collaborative studies are necessary to investigate how each genetic mutation and specific pathogenetic mechanism is correlated to different clinical pictures. Thus, patients need to be included in national observational studies ([@B25], [@B29], [@B30]) or ideally the cohort should be extended to an international perspective ([www.sic-reg.org](https://www.sic-reg.org/)). This management could help us to determine a structured diagnostic algorithm, genetic tools and therapeutic strategies.

In conclusion in more than a half of our children, ES has been earliest manifestation of an underlying immune disorder, in particular when cytopenias were persistent-resistant to therapy, with early onset or associated with lymphadenopathy. We highlighted the importance of a proper laboratory-radiological investigation ([Figure 1](#F1){ref-type="fig"}) and careful follow up of these patients in order to achieve a proper diagnosis and found the best therapeutic strategies. Further investigations are needed to understand the underlying immune dysregulation mechanisms, define markers of disease severity and the benefit--risk profile of second-line therapies.

![In patients with multiple, recurrent, or refractory autoimmune cytopenias and a high clinical suspicion for an underlying disorder if general screening gives positive result further laboratory and radiological analysis should be performed. When a particular clinical suspicious is identified a specific genetic test can be done. In patients with a non-specific profile, considering the declining cost and execution time of new gene sequencing techniques (NGS panel, WES, and NGS), these methodologies are likely to be more time and cost-effective than individual sequencing. \*Red cell antigen typing: C, c, D, E, e, K, Jka, Jkb, Fya, Fyb, S, s, ^\#^Hemolysis indexes: LDH, haptoglobin, bilirubin, ^\~^ T and B maturation and activation: CD4/CD8 T naive (CD45RA+), CD4/CD8 T memory (CD45RO), B naive (CD27--), B memory (CD27+), BCD21loCD38lo, Treg(CD4+CD25+CD127(low/--)), ^∧^DNT: CD3+CD4-CD8-alfa/beta+, ^\>^ ANA, anti-nuclear; ENA, anti-extractable nuclear antigen; aPL, anti-phospholipid; Tg, Thyroglobulin; TPO, Thyroid peroxidase; tTg, tissue transglutaminase IgA and IgG; DGPs, deamidated gliadin peptides; ICA, Autoantibodies against islet cells; GAD, Glutamic acid decarboxylase.](fped-07-00304-g0001){#F1}
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AIHA

:   Autoimmune Hemolytic Anemia

AIN

:   Autoimmune Neutropenia

ALPS

:   Autoimmune Lymphoproliferative Syndrome

ANA

:   Antinuclear Antibody

APS

:   Antiphospholipid Antibody Syndrome

CID

:   Combined Immunodeficiency

CVID

:   Common Variable Immunodeficiency

DNT cell

:   TCRα/β+CD4--CD8-- Double Negative T cell

ES

:   Evans Syndrome

Hb

:   Hemoglobin

IRT

:   Immunoglobulin Replacement Therapy

ITP

:   Immune Thrombocytopenia

Low-B RTS

:   Rubinsten Taybi Syndrome With a Progressive Severe B Cell Deficiency and Hypogammaglobulinemia

MCTD

:   Mixed Connective Tissue Disease

NGS

:   Next Generation Sequencing

PID

:   Primary Immunodeficiencies

SLE

:   Systemic Lupus Erythematosus

WES

:   Whole Exome Sequencing.
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